LTX-401 / Lytix - LARVOL DELTA

Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report (Lytix Biopharma Press Release) - "The ATLAS-IT-05 Phase II study in advanced melanoma was completed, with preparation of the clinical study report ongoing and expected to be finalized in the first quarter of 2026; Evaluating all strategic opportunities to accelerate the development of LTX-401."

Clinical • Trial status • Hepatocellular Cancer • Melanoma

Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 (Lytix Biopharma Press Release) - "LTX-401: New superior formulation with enhanced anticancer effects and extended patent life; clinical trials planned for 2026."

New trial • Oncology